Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched Analysis.
BCG strain
BCG-RIVM
BCG-TICE
bladder cancer
cancer-specific survival
progression-free survival
re-TUR
recurrence-free survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Feb 2022
10 Feb 2022
Historique:
received:
06
01
2022
revised:
01
02
2022
accepted:
06
02
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
26
2
2022
Statut:
epublish
Résumé
Intravesical immunotherapy with bacillus Calmette-Guerin (BCG) is the standard therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The superiority of any BCG strain over another could not be demonstrated yet. Patients with NMIBCs underwent adjuvant induction ± maintenance schedule of intravesical immunotherapy with either BCG TICE or RIVM at two high-volume tertiary institutions. Only BCG-naïve patients and those treated with the same strain over the course of follow-up were included. One-to-one (1:1) propensity score matching (PSM) between the two cohorts was utilized to adjust for baseline demographic and tumor characteristics imbalances. Kaplan-Meier estimates and multivariable Cox regression models according to high-risk NMIBC prognostic factors were implemented to address survival differences between the strains. Sub-group analysis modeling of the influence of routine secondary resection (re-TUR) in the setting of the sole maintenance adjuvant schedule for the two strains was further performed. 852 Ta-T1 NMIBCs ( When routinely performing re-TUR followed by a maintenance BCG schedule, TICE was superior to RIVM for RFS outcomes. However, no significant differences were detected for PFS and CSS, respectively.
Sections du résumé
BACKGROUND
BACKGROUND
Intravesical immunotherapy with bacillus Calmette-Guerin (BCG) is the standard therapy for high-risk non-muscle invasive bladder cancer (NMIBC). The superiority of any BCG strain over another could not be demonstrated yet.
METHODS
METHODS
Patients with NMIBCs underwent adjuvant induction ± maintenance schedule of intravesical immunotherapy with either BCG TICE or RIVM at two high-volume tertiary institutions. Only BCG-naïve patients and those treated with the same strain over the course of follow-up were included. One-to-one (1:1) propensity score matching (PSM) between the two cohorts was utilized to adjust for baseline demographic and tumor characteristics imbalances. Kaplan-Meier estimates and multivariable Cox regression models according to high-risk NMIBC prognostic factors were implemented to address survival differences between the strains. Sub-group analysis modeling of the influence of routine secondary resection (re-TUR) in the setting of the sole maintenance adjuvant schedule for the two strains was further performed.
RESULTS
RESULTS
852 Ta-T1 NMIBCs (
CONCLUSION
CONCLUSIONS
When routinely performing re-TUR followed by a maintenance BCG schedule, TICE was superior to RIVM for RFS outcomes. However, no significant differences were detected for PFS and CSS, respectively.
Identifiants
pubmed: 35205635
pii: cancers14040887
doi: 10.3390/cancers14040887
pmc: PMC8869903
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur Urol. 2015 Jan;67(1):74-82
pubmed: 25043942
J Urol. 2013 Jul;190(1):50-4
pubmed: 23376145
Eur Urol. 2022 Jan;81(1):75-94
pubmed: 34511303
Urol Oncol. 2016 Nov;34(11):484.e19-484.e25
pubmed: 27639776
J Urol. 2002 Nov;168(5):1964-70
pubmed: 12394686
BJU Int. 2018 May;121(5):764-773
pubmed: 29281857
J Urol. 2017 Sep;198(3):503-510
pubmed: 28286068
Clin Infect Dis. 2000 Sep;31 Suppl 3:S86-90
pubmed: 11010830
Vaccine. 2018 Jan 25;36(4):498-506
pubmed: 29254839
Eur Urol. 2013 Mar;63(3):462-72
pubmed: 23141049
Actas Urol Esp (Engl Ed). 2018 May;42(4):238-248
pubmed: 29295749
Eur Urol. 2020 Nov;78(5):690-698
pubmed: 32446864
Urol Int. 2018;101(3):277-284
pubmed: 30227437
Eur Urol. 2014 Oct;66(4):677-88
pubmed: 24674149
Clin Genitourin Cancer. 2020 Feb;18(1):20-25.e2
pubmed: 31786120
Curr Med Res Opin. 2017 Aug;33(8):1379-1387
pubmed: 28471272
J Cancer Res Clin Oncol. 2021 Oct;147(10):3073-3080
pubmed: 33675400
Arab J Urol. 2021 Jan 13;19(1):78-85
pubmed: 33763252
Nat Rev Urol. 2020 Sep;17(9):513-525
pubmed: 32678343
Urology. 2004 Apr;63(4):682-6; discussion 686-7
pubmed: 15072879
Urol Int. 2016;96(1):46-50
pubmed: 26555711
Urol Oncol. 2017 May;35(5):201-207
pubmed: 28041998
Eur Urol. 2021 Jan;79(1):82-104
pubmed: 32360052
J Urol. 1976 Aug;116(2):180-3
pubmed: 820877
J Urol. 2000 Apr;163(4):1124-9
pubmed: 10737480